Article

High expectations in pseudophakes fueling expansion in laser vision correction base

Demand for excellent uncorrected distance visual acuity after cataract surgery is increasing, especially with the availability of new presbyopia-correcting IOLs. This phenomenon is opening up a new class of patients to the benefits of laser vision correction, said Steven J. Dell, MD, at Refractive Surgery Day.

Demand for excellent uncorrected distance visual acuity after cataract surgery is increasing,especially with the availability of new presbyopia-correcting IOLs. This phenomenon is opening up anew class of patients to the benefits of laser vision correction, said Steven J. Dell, MD, atRefractive Surgery Subspecialty Day.

"If cataract surgery is now being considered refractive surgery, then cataract surgery withimplantation of a premium IOL is hyper-refractive surgery," said Dr. Dell, director, refractive andcorneal surgery, Texan Eye, Austin, TX. "Recipients of these lenses are less tolerant of misses inour refractive target than their younger, laser vision correction counterparts. This is because a lowhyperopic result in a young phakic patient may still result in 20/15 vision, but is totallyunacceptable in a pseudophake.

"If refractive errors occur in sphere and/or cylinder, there are a number of options for correctingthem. However, laser vision correction is the most accurate," Dr. Dell said.

When a decision is made to proceed with a laser vision enhancement, surgeons need to consider whetherto perform a customized ablation or a conventional procedure.

Dr. Dell suggested performing a wavefront-guided procedure in the eyes of patients who have receivedeither a monofocal lens, accommodating lens (crystalens, eyeonics), apodized diffractive lens(AcrySof ReSTOR, Alcon Laboratories), or multifocal lens (Tecnis, Advanced Medical Optics), assumingthe wavefront is capturable and the data make sense. However, he cautioned against a customwavefront-guided enhancement in eyes in which the zonal refractive multifocal IOL (ReZoom, AdvancedMedical Optics) is implanted.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.